About Jaguar Health, Inc. 
Jaguar Health, Inc.
Pharmaceuticals & Biotechnology
Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
Company Coordinates 
Company Details
200 PINE STREET SUITE 400 , SAN FRANCISCO CA : 94104
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 3 Schemes (0.24%)
Foreign Institutions
Held by 5 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. James Bochnowski
Independent Chairman of the Board
Ms. Lisa Conte
President, Chief Executive Officer, Director
Mr. Gregory Divis
Independent Director
Mr. John Micek
Independent Director
Mr. Jiahao Qiu
Independent Director
Mr. Jonathan Siegel
Independent Director
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
Pharmaceuticals & Biotechnology
USD 4 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
4.88
-567.44%
0.65






